Amgen boosts guidance ahead of business review

Amgen Inc. (NASDAQ:AMGN) reported 3Q14 non-GAAP EPS of $2.30 and revenues of $5 billion, which beat the Street and represented 19% and 6% growth over 3Q13, respectively. The company also raised its 2014 guidance on revenues to $19.8-$20 billion and EPS to $8.45-$8.55, above the consensus of $19.7 billion and $8.42, respectively.

When asked on its earnings call if the 3Q growth will be sustainable, Tony Hooper, EVP of global commercial operations, deferred to the company's portfolio review meeting Tuesday to discuss performance and future strategies. ...